Alameda, CA-InSite Vision Inc. and Bausch & Lomb have signed a licensing agree-ment to develop InSite's product ISV-403 for the treatment of ocular bacterial infections.
Related Content:
POLL: Will you use biosimilars in your ophthalmic practice?
Ophthalmology set to take the Windy City by storm
Florida appeals court reinstates lawsuit against ophthalmologist
